dichlororibofuranosylbenzimidazole has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkinson, EL | 1 |
| Iegre, J | 1 |
| Brear, PD | 1 |
| Zhabina, EA | 1 |
| Hyvönen, M | 1 |
| Spring, DR | 1 |
1 review available for dichlororibofuranosylbenzimidazole and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.
Topics: Adenosine Triphosphate; Binding Sites; Casein Kinase II; COVID-19; Dichlororibofuranosylbenzimidazol | 2021 |